Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Rev. Soc. Peru. Med. Interna ; 27(1): 19-23, ene.-mar. 2014. tab, graf
Article in Spanish | LILACS, LIPECS | ID: lil-722359

ABSTRACT

Objetivo. Determinar la variabilidad de los valores de hemoglobina tras la administración de metoxipolietilenglicolepoetina beta (M-PEG-E-b) a pacientes en hemodiálisis con anemia. Material y Métodos. Se realizó un estudio observacional descriptivo y retrospectivo en 47 pacientes con enfermedad renal crónica en hemodiálisis del Hospital Nacional de Policía LNS, Lima, durante los meses de enero a junio del 2012, a quienes se le administró M-PEG-E-b una vez al mes en el tratamiento de la anemia.resultadOs. La edad media fue de 63,15 años ± 15,29, con un promedio de 33,5 ± 27,22 meses en hemodiálisis, con un basal de hemoglobina de 8,63 ± 1,66 g/dL. Se encontró que la que la variabilidad de la hemoglobina con la administración mensual de M-PEG-E-b presentó cifras significativas a partir del mes 2; y, el hierro sérico y ferritina a partir del mes 6, sin llegar a niveles óptimo de hemoglobina a los seis meses No se reportaron efectos adversos durante el estudio.cOnclusión. En el manejo de la anemia en pacientes con enfermedad renal crónica en hemodiálisis, la M-PEG-E-b produce variabilidad significativa en los valores de la hemoglobina y de la ferritina, y además es muy bien tolerada.Palabras clave. Hemoglobina, metoxipolietilenglicolepoetina beta, enfermedad renal crónica, anemia.


Introduction. Anemia, a common complication in patients with chronic renal disease, is increased in patients on hemodialysis. Metoxipolyethylenglycol-epoetin beta (MPG-EPO-b), receptor activator erythropoietin is a novel agent for the treatment of anemia in patients with or without dialysis.Objective. To determine the variability of hemoglobin following administration of MPG-EPO-b for the treatment of anemia in patients on hemodialysis. Material and Methods. The present was an observational, descriptive and retrospective study in 47 patients with chronic kidney disease on hemodialysis in the National Hospital Police LNS, Lima, during the months of January to June 2012. They receive MPG-EPO-b for the treatment of anemia.results. The patientÆs mean age was 63,15 years ± 15,29, with an average of 33,5 ± 27,22 months on hemodialysis, with a baseline hemoglobin of 8,63 ± 1,66 g/dL We found that the variability of hemoglobin with monthly administration of MPG-EPO-b increased significantly from month 2 to forth; and, from month 6 for serum iron and ferritin, although it was not reached an optimal hemoglobin levels at six months No adverse effects were reported during study. Sensitivity and specificity for ITB was: 52,9 % and 86,0 %; and SPD: 65,7 % and 84,0 %, respectively. Positive likelihood ratios (LR+) and negative (LR-) for ITB were: 3,78 and 0,55; and DPS: 4,11 and 0,41, respectively. Conclusion. In the management of anemia of patients with chronic renal disease on hemodialysis, metoxi polyethylenglycolepoetin beta produce significant variability in the values of hemoglobin and ferritin, and is very well tolerated.


Subject(s)
Humans , Male , Adult , Female , Young Adult , Middle Aged , Aged, 80 and over , Anemia/therapy , Renal Dialysis , Hemoglobins/administration & dosage , Renal Insufficiency, Chronic , Pharmaceutical Preparations , Epidemiology, Descriptive , Observational Studies as Topic , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL